Core Insights - Kyverna has made significant progress in 2025, reporting positive top-line results from its pivotal study for the autologous CD19 CAR-T therapy, miv-cel, in Stiff-Person syndrome [1] - The company anticipates a transformative period in 2026, with expectations for a Biologics License Application (BLA) submission to address a significant unmet need in a rare disease [1] Company Highlights - The leadership team has undertaken transformative work over the past 18 months to position the company as a leader and differentiate it from competitors in the CAR-T therapy space [2] - The miv-cel construct is unique and specifically designed to enhance therapeutic outcomes [2]